Table 1.
Results of the meta-analysis.
| Outcomes | Number of studies [references] | Number of patients | RR (95% CI) | Heterogeneity | GRADE evidence | |
|---|---|---|---|---|---|---|
| Obese | Non-obese | |||||
| IBD-related surgery | 7 [5,8,15–19] | 1107 | 15113 | 0.82 (0.72, 0.93) | I2=19%, P=0.29 | Moderate |
| Perianal disease | 4 [8,16–18] | 360 | 13297 | 0.97 (0.74, 1.26) | I2=0%, P=0.81 | Moderate |
| Medical treatment | ||||||
| Hormone use | 4 [5,16,17,19] | 814 | 2207 | 0.91 (0.85, 0.98) | I2=0%, P=0.85 | Moderate |
| Anti-TNF use | 3 [5,16,19] | 287 | 906 | 0.89 (0.72, 1.09) | I2=71%, P=0.03 | Low |
| Immunomodulator use | 3 [5,16,19] | 659 | 1415 | 0.96 (0.88,1.06) | I2=0%, P=0.43 | Moderate |
| Hospitalization | 2 [5,19] | 659 | 1415 | 0.84 (0.74, 0.94) | I2=0%, P=0.32 | Moderate |
GRADE Working Group grades of evidence: High quality – further research is very unlikely to change our confidence in the estimate of effect; Moderate quality – further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low quality – further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; RR – risk ratio; GRADE – Grading of Recommendations Assessment, Development and Evaluation; TNF – tumor necrosis factor.